Who are DPT-IPV-Hib-Low（Combined Vaccine）'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DTaP-IPV//PRP~T combined vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dpt-ipv-hib-low-combined-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DPT-IPV-Hib-Low（Combined Vaccine） — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DPT-IPV-Hib-Low（Combined Vaccine） (DPT-IPV-Hib-Low（Combined Vaccine）) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated pentavalent vaccine. Area: Immunology / Infectious Disease Prevention.

phase 3 Inactivated pentavalent vaccine Immunology / Infectious Disease Prevention Biologic Live · refreshed every 30 min

Target snapshot

DPT-IPV-Hib-Low（Combined Vaccine） (DPT-IPV-Hib-Low（Combined Vaccine）) — Tanabe Pharma Corporation. This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b pathogens.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DPT-IPV-Hib-Low（Combined Vaccine） TARGET	DPT-IPV-Hib-Low（Combined Vaccine）	Tanabe Pharma Corporation	phase 3	Inactivated pentavalent vaccine
DTaP-IPV//PRP~T combined vaccine	DTaP-IPV//PRP~T combined vaccine	Sanofi	phase 3	Inactivated pentavalent vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated pentavalent vaccine class)

Sanofi · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DPT-IPV-Hib-Low（Combined Vaccine） — Competitive Intelligence Brief. https://druglandscape.com/ci/dpt-ipv-hib-low-combined-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab